Sign in / Join Now
ETFs & Funds
Neurocrine Biosciences $
screen today. Small drug developer. Looks like a one-time revenue case, not certain though.
Add a reply...
Latest StockTalks »
people get NBIX breaking news and analysis by email alert.
Get email alerts on NBIX »
Neurocrine Biosciences, Inc.
Get latest price
From other sites
Neurocrine Biosciences Breaks Below 200-Day Moving Average - Notable for NBIX
at Nasdaq.com (Oct 11, 2016)
Neurocrine Announces INGREZZA™ (valbenazine) New Drug Application For The Treatment Of Tardive Dyskinesia Has Been Accepted For Priority Review By U.S. FDA
at TheStreet (Oct 11, 2016)
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
at TheStreet (Sep 7, 2016)
Neurocrine Biosciences To Present At The Baird 2016 Healthcare Conference
at TheStreet (Sep 1, 2016)
Neurocrine Announces FDA Conditional Acceptance Of Proprietary Name INGREZZA™ For VMAT2 Inhibitor Valbenazine
at TheStreet (Aug 31, 2016)